Cathie Wood Increases Investment in Veracyte Before Earnings Surprise, Reduces Biotech Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy SRTA?
Source: TipRanks
Portfolio Adjustments: Cathie Wood's Ark Invest has reduced its holdings in several biotech companies, including 10X Genomics and Crispr Therapeutics, indicating a shift away from volatile biotech stocks towards more stable growth sectors.
Investment in Veracyte: Ark made a significant investment in Veracyte, purchasing over 665,690 shares, which saw a strong earnings report that exceeded expectations, leading to a 16% stock surge.
Roku Stake Reduction: The firm also sold more than 1.1 million shares of Roku as part of a strategy to trim its portfolio, influenced by ongoing legal issues facing the company.
Analyst Consensus on Veracyte: Analysts maintain a Moderate Buy consensus on Veracyte, with an average 12-month price target suggesting a potential downside from the current price, reflecting cautious optimism about the stock's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRTA
Wall Street analysts forecast SRTA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.570
Low
8.00
Averages
9.63
High
11.25
Current: 4.570
Low
8.00
Averages
9.63
High
11.25
About SRTA
Strata Critical Medical, Inc. provides time-critical logistics solutions and specialized medical services to healthcare providers across the United States, expanding its portfolio of services through acquisition and organic growth. The Company focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The Company also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strata Critical Medical Reports Strong Q4 2025 Earnings
- Organic Growth Exceeds Expectations: Strata Critical Medical achieved a remarkable 35% organic growth in Q4 2025, with revenue reaching $66.8 million, surpassing expectations and demonstrating strong performance post-Keystone acquisition, thereby solidifying its market position in organ transportation.
- 2026 Guidance Raised: Management raised the 2026 revenue guidance to a range of $260 million to $275 million, with adjusted EBITDA guidance increased to $29 million to $33 million, reflecting ongoing customer growth and robust market demand, indicating enhanced future profitability.
- Acquisition and Asset Strategy: The company plans to add two dedicated aircraft in 2026 to support expansion into new markets while securing a $30 million asset-based credit facility to fund future acquisitions, showcasing its proactive approach in M&A activities.
- Regulatory Policy Benefits: Management highlighted that regulatory policies aimed at incentivizing more DCD donors are a clear positive for the company, leveraging its expertise in organ recovery and transportation to potentially increase market share and business growth opportunities.
See More
Ingram Micro Reports Strong Quarterly Earnings, Shares Surge
- Earnings Beat Expectations: Ingram Micro reported a quarterly adjusted EPS of 96 cents, surpassing the analyst consensus estimate of 88 cents, indicating strong profitability and boosting investor confidence.
- Sales Missed Targets: Despite the positive EPS, the company's quarterly sales were $14.878 billion, falling short of the analyst consensus of $14.073 billion, reflecting challenges in market demand that could impact future growth.
- Stock Price Surge: Following the earnings report, Ingram Micro's shares jumped 11.8% to $23.87, demonstrating a positive market reaction to the company's profitability, potentially attracting more investor interest.
- Overall Market Decline: While Ingram Micro performed well, the broader market saw a decline, with the Dow Jones index dropping over 1,100 points on Tuesday, indicating volatility in market sentiment that could negatively affect other stocks.
See More
Strata Critical Medical Reports 83.5% Revenue Growth in Q4
- Significant Revenue Growth: Strata Critical Medical reported total revenue of $66.79 million in Q4, an 83.5% increase year-over-year, indicating strong market demand in the organ transport sector and potential for further business expansion.
- Surge in Adjusted EBITDA: The company's adjusted EBITDA skyrocketed from $1.08 million last year to $6.96 million, reflecting a 547% increase, which demonstrates substantial improvements in operational efficiency and profitability, thereby boosting investor confidence.
- Optimistic 2026 Outlook: The firm raised its revenue guidance for 2026 to between $260 million and $275 million, representing a growth of approximately 32% to 39% from 2025, showcasing management's strong confidence in future growth potential.
- Successful Acquisition Integration: Following the acquisition of Keystone, over 40% of the logistics revenue growth in Q4 came from Keystone's legacy customers, validating the success of the integration strategy and further solidifying the company's market position.
See More
Strata Critical Medical (SRTA) Earnings Call
See More
Strata Critical Medical Reports 83.5% Revenue Growth in Q4
- Significant Revenue Growth: Strata Critical Medical reported fourth-quarter revenue of $66.8 million, reflecting an impressive 83.5% year-over-year increase, driven by strong performance in its core logistics segment and contributions from the Keystone acquisition, indicating robust growth potential in the organ logistics market.
- Improved Profitability: The company achieved a 90% increase in gross profit to $14.4 million in Q4, with gross margin rising from 20.8% to 21.6%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing the sustainability of future profitability.
- 2026 Outlook Raised: Strata raised its 2026 revenue guidance to a range of $260 million to $275 million, up from previous guidance of $255 million to $270 million, reflecting confidence in future growth, with expected free cash flow of $15 million to $22 million.
- Increased Acquisition Opportunities: Executives highlighted ongoing efforts to pursue multiple acquisition opportunities, aiming for an average annualized adjusted EBITDA growth rate of at least 30% in the coming years, indicating a strategic focus on consolidating its position in the evolving transplant logistics market.
See More
Blade Air Mobility Reports 83.5% Revenue Growth in Q4
- Significant Revenue Growth: Blade Air Mobility reported Q4 2025 revenue of $66.79 million, an impressive 83.5% year-over-year increase, surpassing market expectations by $6.44 million, indicating strong performance and rising demand in the logistics sector.
- Logistics Revenue and Gross Profit Increase: The logistics revenue and gross profit grew by 35.3% and 39.5% respectively in Q4, demonstrating Strata's robust organic growth momentum and solidifying its competitive position in the industry.
- Reduced Net Loss: The net loss from continuing operations decreased by $2.0 million year-over-year to $(5.4) million, compared to $(7.4) million in the prior year, reflecting improvements in cost control and operational efficiency.
- Upgraded 2026 Financial Outlook: Blade Air Mobility raised its 2026 revenue and adjusted EBITDA guidance, now expecting revenue between $260 million and $275 million and adjusted EBITDA between $29 million and $33 million, showcasing confidence in future growth prospects.
See More
Strata Critical Medical Reports Strong Q4 2025 Earnings
- Organic Growth Exceeds Expectations: Strata Critical Medical achieved a remarkable 35% organic growth in Q4 2025, with revenue reaching $66.8 million, surpassing expectations and demonstrating strong performance post-Keystone acquisition, thereby solidifying its market position in organ transportation.
- 2026 Guidance Raised: Management raised the 2026 revenue guidance to a range of $260 million to $275 million, with adjusted EBITDA guidance increased to $29 million to $33 million, reflecting ongoing customer growth and robust market demand, indicating enhanced future profitability.
- Acquisition and Asset Strategy: The company plans to add two dedicated aircraft in 2026 to support expansion into new markets while securing a $30 million asset-based credit facility to fund future acquisitions, showcasing its proactive approach in M&A activities.
- Regulatory Policy Benefits: Management highlighted that regulatory policies aimed at incentivizing more DCD donors are a clear positive for the company, leveraging its expertise in organ recovery and transportation to potentially increase market share and business growth opportunities.
See More
Ingram Micro Reports Strong Quarterly Earnings, Shares Surge
- Earnings Beat Expectations: Ingram Micro reported a quarterly adjusted EPS of 96 cents, surpassing the analyst consensus estimate of 88 cents, indicating strong profitability and boosting investor confidence.
- Sales Missed Targets: Despite the positive EPS, the company's quarterly sales were $14.878 billion, falling short of the analyst consensus of $14.073 billion, reflecting challenges in market demand that could impact future growth.
- Stock Price Surge: Following the earnings report, Ingram Micro's shares jumped 11.8% to $23.87, demonstrating a positive market reaction to the company's profitability, potentially attracting more investor interest.
- Overall Market Decline: While Ingram Micro performed well, the broader market saw a decline, with the Dow Jones index dropping over 1,100 points on Tuesday, indicating volatility in market sentiment that could negatively affect other stocks.
See More
Strata Critical Medical Reports 83.5% Revenue Growth in Q4
- Significant Revenue Growth: Strata Critical Medical reported total revenue of $66.79 million in Q4, an 83.5% increase year-over-year, indicating strong market demand in the organ transport sector and potential for further business expansion.
- Surge in Adjusted EBITDA: The company's adjusted EBITDA skyrocketed from $1.08 million last year to $6.96 million, reflecting a 547% increase, which demonstrates substantial improvements in operational efficiency and profitability, thereby boosting investor confidence.
- Optimistic 2026 Outlook: The firm raised its revenue guidance for 2026 to between $260 million and $275 million, representing a growth of approximately 32% to 39% from 2025, showcasing management's strong confidence in future growth potential.
- Successful Acquisition Integration: Following the acquisition of Keystone, over 40% of the logistics revenue growth in Q4 came from Keystone's legacy customers, validating the success of the integration strategy and further solidifying the company's market position.
See More
Strata Critical Medical (SRTA) Earnings Call
See More
Strata Critical Medical Reports 83.5% Revenue Growth in Q4
- Significant Revenue Growth: Strata Critical Medical reported fourth-quarter revenue of $66.8 million, reflecting an impressive 83.5% year-over-year increase, driven by strong performance in its core logistics segment and contributions from the Keystone acquisition, indicating robust growth potential in the organ logistics market.
- Improved Profitability: The company achieved a 90% increase in gross profit to $14.4 million in Q4, with gross margin rising from 20.8% to 21.6%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing the sustainability of future profitability.
- 2026 Outlook Raised: Strata raised its 2026 revenue guidance to a range of $260 million to $275 million, up from previous guidance of $255 million to $270 million, reflecting confidence in future growth, with expected free cash flow of $15 million to $22 million.
- Increased Acquisition Opportunities: Executives highlighted ongoing efforts to pursue multiple acquisition opportunities, aiming for an average annualized adjusted EBITDA growth rate of at least 30% in the coming years, indicating a strategic focus on consolidating its position in the evolving transplant logistics market.
See More
Blade Air Mobility Reports 83.5% Revenue Growth in Q4
- Significant Revenue Growth: Blade Air Mobility reported Q4 2025 revenue of $66.79 million, an impressive 83.5% year-over-year increase, surpassing market expectations by $6.44 million, indicating strong performance and rising demand in the logistics sector.
- Logistics Revenue and Gross Profit Increase: The logistics revenue and gross profit grew by 35.3% and 39.5% respectively in Q4, demonstrating Strata's robust organic growth momentum and solidifying its competitive position in the industry.
- Reduced Net Loss: The net loss from continuing operations decreased by $2.0 million year-over-year to $(5.4) million, compared to $(7.4) million in the prior year, reflecting improvements in cost control and operational efficiency.
- Upgraded 2026 Financial Outlook: Blade Air Mobility raised its 2026 revenue and adjusted EBITDA guidance, now expecting revenue between $260 million and $275 million and adjusted EBITDA between $29 million and $33 million, showcasing confidence in future growth prospects.
See More
